Keith T. Flaherty, MD

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.

Keith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br /> &nbsp;

Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in BRAF-mutant melanoma during the 2018 ASCO Annual Meeting.

Keith T. Flaherty, MD, provides an overview of the phase III COMBI-d study, which examined the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment of patients with BRAF-mutant metastatic melanoma.